Core B: Clinical recruits, assesses, and follows all participants in the ADRC Cohort. It uses well-established informant-based clinical and psychometric instruments (including the Uniform Data Set) at entry and annually thereafter to obtain clinical, cognitive, behavioral, and neurological data to carefully characterize each participant as to the presence or absence of dementia and, when present, its severity and etiology. The Core has successfully provided participants, tissue, and data to all requesting Cores and Projects since its inception in 1985 and will continue to do so in the next 5-year funding period. On a daily basis, the Core interacts directly or indirectly with every facet of the ADRC. The Core's Specific Aims in the proposed funding period are: 1. Maintain an active longitudinal Cohort of ~ 300 participants, cognitively normal and with DAT, of individuals 65 years or more by annually enrolling 30 new participants to replenish attritional loss and to serve Projects 1 and 3 of this competing renewal application. 2. Ensure that Cohort participants contribute to the imaging, biofluid, and DNA (Core F: Genetics) protocols of the ADRC and its affiliated grants and obtain autopsies in deceased participants for Core D: Neuropathology. 3. Support the Core's African American Outreach Satellite. 4. Coordinate with Core C: Data Management and Statistics to integrate data procedures and respond to data sharing initiatives. 5. Coordinate the Core A: Administration to maintain the ADRC's contributions to multicenter collaborative studies, including the National Alzheimer's Coordinating Center. 6. Interact cooperatively with Core E: Education and Information Transfer and its Rural Education and Outreach Satellite to further the educational, training, and outreach goals of the ADRC.
The ADRC Clinical Core maintains a cohort of longitudinally studied, well-characterized individuals with DAT and cognitively normal control individuals is required to investigate the critical relationships between healthy brain aging and Alzheimer's disease (AD). The WU ADRC Clinical Core has focused on the early detection of DAT in comparison with nondemented aging. The WU ADRC has developed clinical instruments, research findings, and concepts that have influenced the field.
|Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148|
|Wildburger, Norelle C; Esparza, Thomas J; LeDuc, Richard D et al. (2017) Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. Sci Rep 7:9520|
|Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528|
|Roe, Catherine M; Babulal, Ganesh M; Head, Denise M et al. (2017) Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimers Dement (N Y) 3:74-82|
|Neu, Scott C; Pa, Judy; Kukull, Walter et al. (2017) Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74:1178-1189|
|Miller-Thomas, Michelle M; Benzinger, Tammie L S (2017) Neurologic Applications of PET/MR Imaging. Magn Reson Imaging Clin N Am 25:297-313|
|Alosco, Michael L; Duskin, Jonathan; Besser, Lilah M et al. (2017) Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set. J Alzheimers Dis 57:953-968|
|Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2017) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord 31:69-72|
|Pandya, Seema Y; Lacritz, Laura H; Weiner, Myron F et al. (2017) Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition. Dement Geriatr Cogn Disord 43:204-214|
|Lewczuk, Piotr; Matzen, Anja; Blennow, Kaj et al. (2017) Cerebrospinal Fluid A?42/40 Corresponds Better than A?42 to Amyloid PET in Alzheimer's Disease. J Alzheimers Dis 55:813-822|
Showing the most recent 10 out of 825 publications